title: Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
abstract: OBJECTIVE
  To assess the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise in subjects with severe chronic obstructive pulmonary disease (COPD), referred for myocardial perfusion imaging (MPI).
  
  
  METHODS
  We studied prospectively 12 male patients with severe COPD. Stress was 4min of low-level exercise with bolus injection of regadenoson (0.4mg) at 1.5min, followed by (99m)Tc-MPI agent injection. Demographics, medical history, lung medications, adverse events, oxygen saturation (SatO2), MPI findings for coronary artery disease (CAD), and changes in systolic blood pressure (SBP), and heart rate (HR) were registered.
  
  
  RESULTS
  The observed adverse event profile of regadenoson was similar to that of patients with mild-moderate COPD. There was no clinical exacerbation of COPD. Adverse events were self-limiting: dyspnea (33.3%), fatigue (25.0%), chest pain, headache (16.7%, respectively), and gastrointestinal discomfort, dry mouth, flushing, feeling hot and dizziness (8.3%, respectively). 25.0% of patients did not report any symptoms. We observed significant increases in SBP and HR from baseline (142.6mmHg±22.3 vs 152.5mmHg±18.5, and 80 b.p.m.±18 vs 105 b.p.m.±22, respectively; p<0.05).
  
  
  CONCLUSIONS
  Regadenoson combined with low-level exercise is safe and well tolerated in stable patients with severe COPD undergoing MPI.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain. Electronic address: carlosd.salgado.sspa@juntadeandalucia.es.
authors.forename: C
authors.initials: C
authors.lastname: Salgado-Garcia
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Jimenez-Heffernan
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Ramos-Font
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Lopez-Martin
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Sanchez-de-Mora
authors.affiliation: Servicio de Medicina Nuclear, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Aroui
authors.affiliation: Servicio de Cardiología, Hospital Juan Ramón Jiménez, Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005 Huelva, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Lopez-Aguilar
authors.affiliation: Área de Metodología y Ciencias del Comportamiento, Universidad de Sevilla, 41018 Sevilla, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Rivera-de-Los-Santos
authors.affiliation: Departamento de Biología Ambiental y Salud Pública, Universidad de Huelva, Huelva, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Ruiz-Frutos
mesh_terms: D058908:Adenosine A2 Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D005080:Exercise Test; D006801:Humans; D008297:Male; D055414:Myocardial Perfusion Imaging; D010865:Pilot Projects; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D058908:Adenosine A2 Receptor Agonists; D011687:Purines; D011720:Pyrazoles; C430916:regadenoson
keywords: Adverse events; Efectos adversos; Enfermedad pulmonar obstructiva crónica severa; Myocardial perfusion imaging; Perfusión miocárdica; Regadenoson; Regadenosón; Safety; Seguridad; Severe chronic obstructive pulmonary disease